New insider activity at Stoke Therapeutics ( (STOK) ) has taken place on August 20, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Stoke Therapeutics stock, CMO Barry Ticho sold 2,805 shares valued at $51,135. Director Edward Kaye parted with 12,126 shares, amounting to $221,056. Additionally, GC & CORP SEC Jonathan Allan sold 1,683 shares for a total of $30,681.
Recent Updates on STOK stock
In the last 24 hours, Stoke Therapeutics has seen a slight adjustment in its stock price target by BTIG analyst Thomas Shrader, who lowered it due to the company’s 36-month data for Zorevunersen. The data showed significant seizure reductions in patients, particularly those who started on optimal loading doses, which supports the drug’s efficacy. Additionally, Stoke Therapeutics reported strong Q2 financial results, with revenues rising to $13.8 million from $4.8 million the previous year, driven by collaborations with Acadia Pharmaceuticals and Biogen. Despite a net loss of $23.5 million, the company maintains a solid cash reserve expected to fund operations through mid-2028. The ongoing progress in clinical trials, including the Phase 3 EMPEROR study for Dravet syndrome and the initiation of a Phase 1 study for STK-002 in ADOA, along with promising long-term data, continues to bolster the company’s outlook and investor confidence.
Spark’s Take on STOK Stock
According to Spark, TipRanks’ AI Analyst, STOK is a Neutral.
Stoke Therapeutics’ overall stock score reflects strong financial performance and positive corporate developments, particularly the initiation of a significant Phase 3 study. However, technical indicators suggest caution due to overbought conditions, and the valuation is moderate with no dividend yield. Historical financial volatility remains a risk factor.
To see Spark’s full report on STOK stock, click here.
More about Stoke Therapeutics
YTD Price Performance: 64.06%
Average Trading Volume: 712,596
Technical Sentiment Signal: Buy
Current Market Cap: $1.01B